|Bid||0.0000 x 2200|
|Ask||0.0000 x 1100|
|Day's range||2.5900 - 2.7600|
|52-week range||0.7800 - 5.9800|
|Beta (5Y monthly)||N/A|
|PE ratio (TTM)||N/A|
|Earnings date||28 Jul 2021 - 02 Aug 2021|
|Forward dividend & yield||N/A (N/A)|
|1y target est||8.50|
Infinity (INFI) delivered earnings and revenue surprises of -7.14% and 0.86%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) ("Infinity" or the "Company"), a clinical-stage biotechnology company developing eganelisib (IPI-549), a potentially first-in-class, oral, immuno-oncology macrophage reprogramming therapeutic, today announced its first quarter 2021 financial results and provided a corporate update.
Infinity Pharmaceuticals, Inc. (NASDAQ: INFI), a clinical-stage biotechnology company developing eganelisib, a potentially first-in-class, oral, immuno-oncology macrophage reprogramming therapeutic that addresses a fundamental biologic mechanism of immune suppression in cancer, will host a conference call on Thursday, May 13th 2021 at 4:30pm ET to report its financial results for the first quarter of 2021.